Genetic human Trx1-transgenic (Trx1-Tg) donor T cells or administration of human recombinant Trx1 to recipients of allogeneic hematopoietic transplantation (allo-HCT) could both considerably lessen the severity of graft-versus-host disease (GVHD) 45. This evidence concerns the gene TXN and graft versus host disease.